Excel Industries Ltd
Excel Industries is engaged in manufacturing and selling of Chemicals, Pharma intermediates and Environmental products. [1]
- Market Cap ₹ 1,159 Cr.
- Current Price ₹ 922
- High / Low ₹ 1,452 / 798
- Stock P/E 16.5
- Book Value ₹ 985
- Dividend Yield 1.49 %
- ROCE 9.45 %
- ROE 6.92 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
- Stock is trading at 0.94 times its book value
- Company has been maintaining a healthy dividend payout of 28.2%
Cons
- The company has delivered a poor sales growth of 6.84% over past five years.
- Company has a low return on equity of 5.38% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE SmallCap BSE Allcap BSE Commodities
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 416 | 482 | 435 | 446 | 582 | 825 | 702 | 749 | 1,178 | 1,090 | 826 | 978 | 1,024 | |
| 376 | 409 | 372 | 402 | 457 | 574 | 571 | 627 | 946 | 960 | 800 | 855 | 919 | |
| Operating Profit | 40 | 72 | 62 | 44 | 125 | 251 | 131 | 122 | 232 | 129 | 26 | 123 | 105 |
| OPM % | 10% | 15% | 14% | 10% | 21% | 30% | 19% | 16% | 20% | 12% | 3% | 13% | 10% |
| 4 | 7 | 2 | 9 | 3 | 4 | 8 | 8 | 14 | 9 | 29 | 25 | 25 | |
| Interest | 12 | 14 | 13 | 11 | 7 | 3 | 4 | 3 | 3 | 3 | 3 | 4 | 2 |
| Depreciation | 11 | 15 | 15 | 14 | 15 | 18 | 23 | 27 | 31 | 31 | 31 | 34 | 35 |
| Profit before tax | 21 | 50 | 37 | 28 | 106 | 233 | 112 | 100 | 212 | 104 | 20 | 111 | 93 |
| Tax % | 15% | 19% | 31% | 25% | 31% | 35% | 17% | 30% | 24% | 25% | 25% | 25% | |
| 17 | 41 | 25 | 21 | 73 | 152 | 93 | 70 | 160 | 78 | 15 | 84 | 70 | |
| EPS in Rs | 16.03 | 34.07 | 19.53 | 16.55 | 57.71 | 120.96 | 74.36 | 55.84 | 127.41 | 62.41 | 12.02 | 66.42 | 55.73 |
| Dividend Payout % | 23% | 21% | 23% | 36% | 22% | 16% | 13% | 20% | 18% | 18% | 46% | 21% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 7% |
| 3 Years: | -6% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | -4% |
| 3 Years: | -21% |
| TTM: | -8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 1% |
| 3 Years: | -9% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | 5% |
| Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 145 | 178 | 201 | 352 | 434 | 584 | 595 | 710 | 926 | 985 | 1,069 | 1,171 | 1,231 |
| 102 | 95 | 89 | 68 | 10 | 7 | 24 | 9 | 7 | 3 | 2 | 12 | 11 | |
| 97 | 106 | 121 | 132 | 167 | 181 | 197 | 229 | 292 | 230 | 334 | 272 | 360 | |
| Total Liabilities | 349 | 384 | 418 | 559 | 618 | 779 | 823 | 953 | 1,232 | 1,225 | 1,412 | 1,461 | 1,609 |
| 128 | 157 | 164 | 180 | 199 | 235 | 376 | 389 | 427 | 428 | 424 | 455 | 452 | |
| CWIP | 20 | 3 | 3 | 8 | 23 | 12 | 10 | 17 | 21 | 19 | 19 | 13 | 29 |
| Investments | 14 | 14 | 14 | 152 | 175 | 261 | 156 | 209 | 295 | 359 | 606 | 635 | 647 |
| 187 | 210 | 237 | 218 | 220 | 272 | 281 | 339 | 489 | 419 | 363 | 359 | 481 | |
| Total Assets | 349 | 384 | 418 | 559 | 618 | 779 | 823 | 953 | 1,232 | 1,225 | 1,412 | 1,461 | 1,609 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 | 44 | 46 | 35 | 120 | 135 | 110 | 90 | 109 | 127 | 93 | 63 | |
| -32 | -27 | -27 | 12 | -48 | -109 | -65 | -48 | -106 | -117 | -72 | -46 | |
| 20 | -23 | -17 | -48 | -73 | -24 | -31 | -17 | -17 | -35 | -17 | -16 | |
| Net Cash Flow | 1 | -5 | 1 | -1 | -2 | 2 | 14 | 25 | -14 | -25 | 4 | 2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 89 | 80 | 107 | 95 | 75 | 68 | 78 | 84 | 62 | 52 | 82 | 81 |
| Inventory Days | 74 | 103 | 102 | 84 | 76 | 72 | 90 | 71 | 103 | 78 | 80 | 70 |
| Days Payable | 81 | 84 | 115 | 98 | 123 | 106 | 122 | 126 | 112 | 64 | 139 | 102 |
| Cash Conversion Cycle | 82 | 99 | 93 | 81 | 27 | 33 | 46 | 29 | 52 | 67 | 23 | 49 |
| Working Capital Days | 15 | 27 | 29 | 46 | 54 | 58 | 48 | 50 | 60 | 60 | 47 | 57 |
| ROCE % | 14% | 24% | 17% | 11% | 26% | 45% | 19% | 15% | 26% | 11% | 2% | 9% |
Documents
Announcements
-
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
21 Nov - Subsidiaries sold 19.99% each in Mobitrash to Ashwin C. Shroff on 21 Nov 2025 for Rs19,990 each.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
20 Nov - Q2/H1 FY26 earnings call: 5‑year contract (Rs40cr capex; Rs25cr advance), Rs35‑40cr annual revenue; biocide commissioned; H1 revenue Rs580cr
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
14 Nov - Uploaded audio recording of Q2 & H1 FY26 earnings call held 14-Nov-2025.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
14 Nov - Listing Obligations and Disclosures Requirements) Regulations, 2015, we enclose herewith the revised Investor Presentation on the Unaudited Financial Results for the quarter and half year …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
13 Nov - Listing Obligation and Disclosure Requirements) Regulation, 2015, we enclose herewith the investor Presentation on the Unaudited Financial Results for the quarter and half year ended …
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2025Transcript PPT
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
Market Position
The company is the No. 1 Producer of DETC (Diethylthiophosphoryl Chloride) and one of the Top 5 Producers of Phosphonates in the world. [1]